C4 Therapeutics (NAS:CCCC) ROE % Adjusted to Book Value

: -48.97% (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

C4 Therapeutics's ROE % for the quarter that ended in Dec. 2022 was -48.97%. C4 Therapeutics's PB Ratio for the quarter that ended in Dec. 2022 was 1.00. C4 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was -48.97%.

C4 Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for C4 Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

-15.47

-6.23

-37.76

C4 Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROE % Adjusted to Book Value												-3.95	-10.35	-28.91	-28.57	-48.97

Competitive Comparison

For the Biotechnology subindustry, C4 Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

C4 Therapeutics ROE % Adjusted to Book Value Distribution

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's ROE % Adjusted to Book Value falls in comparison to its industry or sector. The grey bar indicates the ROE % Adjusted to Book Value's extreme value range as defined by GuruFocus.

C4 Therapeutics ROE % Adjusted to Book Value Calculation

C4 Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-37.76%	/	1.00
	=	-37.76%

C4 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-48.97%	/	1.00
	=	-48.97%

C4 Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

C4 Therapeutics (NAS:CCCC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472

Website

https://www.c4therapeutics.com

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Executives

Laura Bessen	director	4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Scott N Boyle	officer: Chief Business Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kelly Schick	officer: Chief People Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Utpal Koppikar	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Lauren White	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Glenn Dubin	director	C/O HIGHBRIDGE CAPITAL MANAGEMENT, LLC, 40 WEST 57TH STREET, 32ND FLOOR, NEW YORK NY 10019
Marc A Cohen	director, 10 percent owner, officer: Chief Executive Officer	1000 WILSON BLVD. #1800, ARLINGTON VA 22209
Alain J Cohen	director, 10 percent owner	7255 WOODMONT AVE, BETHESDA MD 20814
Elena Prokupets	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kenneth Carl Anderson	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel	officer: Chief Legal Officer	C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher	officer: Chief Scientific Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Laura Jean Wahlberg	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472